Importantly, C/M@Alb NCs exhibited enhanced and albumin receptor-mediated cellular uptake, intracellular ROS scavenging ability, extended blood residence time, and favorable tumor accumulation and LN extravasation, finally leading to the potent antitumor efficacy against HT-29 subcutaneous colon tumors, E0771 orthotopic breast tumors, as well as PDX primary lung tumors with reduced systemic toxicity, providing a clinically satisfactory strategy for enhancing the therapeutic efficacy and clinical translation. This evidence concerns the gene ALB and colonic neoplasm.